DE1467889A1 - Verfahren zur Herstellung stabiler Heparinloesungen - Google Patents
Verfahren zur Herstellung stabiler HeparinloesungenInfo
- Publication number
- DE1467889A1 DE1467889A1 DE19641467889 DE1467889A DE1467889A1 DE 1467889 A1 DE1467889 A1 DE 1467889A1 DE 19641467889 DE19641467889 DE 19641467889 DE 1467889 A DE1467889 A DE 1467889A DE 1467889 A1 DE1467889 A1 DE 1467889A1
- Authority
- DE
- Germany
- Prior art keywords
- heparin
- solution
- production
- solutions
- stable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000669 heparin Polymers 0.000 title claims description 41
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims description 38
- 229960002897 heparin Drugs 0.000 title claims description 38
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 238000000034 method Methods 0.000 title claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 239000000243 solution Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000002784 sclerotic effect Effects 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 206010046996 Varicose vein Diseases 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 208000027185 varicose disease Diseases 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000002429 anti-coagulating effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEF0043156 | 1964-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1467889A1 true DE1467889A1 (de) | 1969-07-03 |
Family
ID=7099421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19641467889 Pending DE1467889A1 (de) | 1964-06-12 | 1964-06-12 | Verfahren zur Herstellung stabiler Heparinloesungen |
Country Status (5)
| Country | Link |
|---|---|
| BE (1) | BE649338A (enrdf_load_stackoverflow) |
| DE (1) | DE1467889A1 (enrdf_load_stackoverflow) |
| FR (1) | FR3716M (enrdf_load_stackoverflow) |
| GB (1) | GB1034536A (enrdf_load_stackoverflow) |
| NL (1) | NL6406775A (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4039665A (en) * | 1975-05-20 | 1977-08-02 | William T. Foley Foundation, Inc. | Method for the eradication of venous blemishes |
| FR2616661B1 (fr) * | 1987-06-19 | 1991-06-07 | Doutremepuich Christian | Composition a base de mucopolysaccharides hepariniques, active par voie orale |
| CN118384106B (zh) * | 2024-04-26 | 2024-11-05 | 烟台东诚北方制药有限公司 | 一种澄清稳定的依诺肝素钠注射液的制备方法 |
-
1964
- 1964-06-12 DE DE19641467889 patent/DE1467889A1/de active Pending
- 1964-06-15 NL NL6406775A patent/NL6406775A/xx unknown
- 1964-06-15 GB GB24678/64A patent/GB1034536A/en not_active Expired
- 1964-06-16 FR FR978366A patent/FR3716M/fr active Active
- 1964-06-16 BE BE649338D patent/BE649338A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR3716M (fr) | 1965-11-29 |
| NL6406775A (enrdf_load_stackoverflow) | 1965-12-16 |
| BE649338A (enrdf_load_stackoverflow) | 1964-10-16 |
| GB1034536A (en) | 1966-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE4344824C1 (de) | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung | |
| DE2324717B2 (de) | Verfahren zur Herstellung eines stabilen AHF-Konzentrates (Faktor VUI) | |
| CH652031A5 (de) | Stabilisierte insulinpraeparate und verfahren zu deren herstellung. | |
| DE2417859C2 (de) | Verfahren zur Herstellung von einfachen oder gemischten Heparinsalzen und diese enthaltende Arzneimittel | |
| DE602005002495T2 (de) | Injizierbare Formulierung mit Natriumdiclofenac, Beta-Cyclodextrin und einem Polysorbat | |
| DE2604481C2 (enrdf_load_stackoverflow) | ||
| DE1915798C3 (de) | Antacidum-Präparat in Form einer wäßrigen Suspension | |
| DE1467889A1 (de) | Verfahren zur Herstellung stabiler Heparinloesungen | |
| DE4010536C2 (enrdf_load_stackoverflow) | ||
| DE1667914A1 (de) | Arzneimittelzusammensetzung | |
| DE2546474A1 (de) | Injizierbares pharmazeutisches thyroxinpraeparat und verfahren zu dessen herstellung | |
| DE3023396C2 (de) | Arzneimittel zur intravenösen Krebstherapie | |
| DE2556001C3 (de) | Spritzfertige injizierbare Lösungen mit einem Gehalt an Alkalicanrenoat | |
| DE1179331B (de) | Verfahren zur Entgiftung und Wiederherstellung des Ionengleichgewichtes von citratiertem Blut | |
| DE2233816C3 (de) | Stabiles antikoagulanshaltiges Vollblut | |
| DE2404620C3 (de) | Infusionslösung zur Behandlung tachykarder Herzrhythmusstörungen | |
| Salant et al. | THE INFLUENCE OF IODIN AND SODIUM IODID ON THE CIRCULATION | |
| DE4100782A1 (de) | Waessrige ozonpraeparate, verfahren zu ihrer herstellung und ihre verwendung | |
| AT215736B (de) | Verfahren zur Herstellung von intravenös injizierbaren Kombinationspräparaten zur Bekämpfung von Endoparasiten in Säugetieren | |
| AT221230B (enrdf_load_stackoverflow) | ||
| DE1467991A1 (de) | Arzneimittel und chemische Zubereitungen | |
| DE658211C (de) | Verfahren zur Herstellung einer therapeutisch verwendbaren Loesung von Galle | |
| DE695906C (de) | Mittel zur Anregung und Foerderung des Wurzelwachstums | |
| DE1617540A1 (de) | Verfahren zur Herstellung eines injizierbaren pharmazeutischen Thyroxinpraeparates | |
| CH338814A (de) | Verfahren zur Herstellung eines kolloidalen Eisenpräparates |